Last reviewed · How we verify

Guangzhou Bio-gene Technology Co., Ltd — Portfolio Competitive Intelligence Brief

Guangzhou Bio-gene Technology Co., Ltd pipeline: 0 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Celgene · 1 shared drug class
  2. Celyad Oncology SA · 1 shared drug class
  3. Chongqing Precision Biotech Co., Ltd · 1 shared drug class
  4. EdiGene Inc. · 1 shared drug class
  5. Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 shared drug class
  6. Guangzhou Women and Children's Medical Center · 1 shared drug class
  7. Hrain Biotechnology Co., Ltd. · 1 shared drug class
  8. Beijing Yongtai Ruike Biotechnology Company Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Guangzhou Bio-gene Technology Co., Ltd:

Cite this brief

Drug Landscape (2026). Guangzhou Bio-gene Technology Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/guangzhou-bio-gene-technology-co-ltd. Accessed 2026-05-16.

Related